IP Verse

Modulation Of Afucosylated Species In A Monoclonal Antibody Composition - EP3400241

The patent EP3400241 was granted to Oncobiologics on Jul 22, 2020. The application was originally filed on Jan 5, 2017 under application number EP17702444A. The patent is currently recorded with a legal status of "Revoked".

EP3400241

ONCOBIOLOGICS
Application Number
EP17702444A
Filing Date
Jan 5, 2017
Status
Revoked
Apr 29, 2022
Publication Date
Jul 22, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PATENTANWALTE ISENBRUCK BOSL HORSCHLER PARTG MBBApr 21, 2021LAHRTZADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS6090382
INTERNATIONAL-SEARCH-REPORTWO2010141855
INTERNATIONAL-SEARCH-REPORTWO2012041768
INTERNATIONAL-SEARCH-REPORTWO2013114165
INTERNATIONAL-SEARCH-REPORTWO2014055370
INTERNATIONAL-SEARCH-REPORTWO2015140700
OPPOSITIONWO2005089182
OPPOSITIONWO2006125821
OPPOSITIONWO2007115813
OPPOSITIONWO2010141478
OPPOSITIONWO2010141855
OPPOSITIONWO2012041768
OPPOSITIONWO2014055370

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- IMAI-NISHIYA HARUE ET AL, "Double knockdown of Î+-1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC", BMC BIOTECHNOLOGY, BIOMED CENTRAL LTD. LONDON, GB, (20071130), vol. 7, no. 1, ISSN 1472-6750, page 84, XP021035667 [Y] 1-42 * the whole document *
INTERNATIONAL-SEARCH-REPORT- YAMANE-OHNUKI NAOKO ET AL, "Production of therapeutic antibodies with controlled fucosylation", MABS, LANDES BIOSCIENCE, US, (20090501), vol. 1, no. 3, ISSN 1942-0870, pages 230 - 236, XP002630025 [A] 1-42 * the whole document *
INTERNATIONAL-SEARCH-REPORT- ZHOU QUIN ET AL, "Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function", BIOTECHNOLOGY AND BIOENGINEERING, WILEY ETC, (20080201), vol. 99, no. 3, doi:10.1002/BIT.21598, ISSN 0006-3592, pages 652 - 665, XP009137262 [Y] 1-42 * the whole document *
INTERNATIONAL-SEARCH-REPORT- KATSUHIRO MORI ET AL, "Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies", CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, (20071031), vol. 55, no. 2-3, doi:10.1007/S10616-007-9103-2, ISSN 1573-0778, pages 109 - 114, XP019550382 [A] 1-42 * the whole document *
INTERNATIONAL-SEARCH-REPORT- KANDA ET AL, "Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, (20070619), vol. 130, no. 3, doi:10.1016/J.JBIOTEC.2007.04.025, ISSN 0168-1656, pages 300 - 310, XP022119693 [Y] 1-42 * the whole document *
INTERNATIONAL-SEARCH-REPORT- JOHN G. ALLEN ET AL, "Facile Modulation of Antibody Fucosylation with Small Molecule Fucostatin Inhibitors and Cocrystal Structure with GDP-Mannose 4,6-Dehydratase", ACS CHEMICAL BIOLOGY, US, (20161021), vol. 11, no. 10, doi:10.1021/acschembio.6b00460, ISSN 1554-8929, pages 2734 - 2743, XP055352875 [YP] 1-42 * the whole document *
INTERNATIONAL-SEARCH-REPORT- VON HORSTEN H H ET AL, "Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 20, no. 12, doi:10.1093/GLYCOB/CWQ109, ISSN 0959-6658, (20101201), pages 1607 - 1618, (20100715), XP002612500 [Y] 1-42 * the whole document *
INTERNATIONAL-SEARCH-REPORT- ANA RITA COSTA ET AL, "The impact of microcarrier culture optimization on the glycosylation profile of a monoclonal antibody", SPRINGERPLUS, DE, (20130128), vol. 2, no. 1, doi:10.1186/2193-1801-2-25, ISSN 2193-1801, page 25, XP055345245 [Y] 1-42 * the whole document *
INTERNATIONAL-SEARCH-REPORT- SATOH MITSUO ET AL, "NON-FUCOSYLATED THERAPEUTIC ANTIBODIES AS NEXT-GENERATION THERAPEUTIC ANTIBODIES", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, ASHLEY, LONDON; GB, (20061101), vol. 6, no. 11, doi:10.1517/14712598.6.11.1161, ISSN 1471-2598, pages 1161 - 1173, XP008078583 [A] 1-42 * the whole document *
OPPOSITION- YAMANE-OHNUKI et al., "Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity", Biotechnol Bioeng, (20040905), vol. 87, no. 5, doi:10.1002/bit.20151, pages 614 - 22, XP002984450
OPPOSITION- ZHOU et al., "Development of a simple and rapid method for producing non- fucosylated oligomannose containing antibodies with increased effector function", Biotechnol Bioeng, (20080215), vol. 99, no. 3, doi:10.1002/bit.21598, pages 652 - 65, XP009137262
OPPOSITION- KHATTAK et al., "Feed development for fed-batch CHO production process by semisteady state analysis", Biotechnol Prog, (20100500), vol. 26, no. 3, doi:10.1002/btpr.362, pages 797 - 804, XP055440182
OPPOSITION- KONNO et al., "Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity", Cytotechnology, (20120500), vol. 64, no. 3, doi:10.1007/s10616-011-9377-2, pages 249 - 65, XP055247203
OPPOSITION- Freimoser-Grundschober Anne; Rueger Petra; Fingas Felix; Sondermann Peter; Herter Sylvia; Schlothauer Tilman; Umana Pablo; Neumann Christiane, "FcyRIIIa chromatography to enrich alpha-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies", J Chromatogr A, (20200111), vol. 1610, no. 460554, pages 1 - 9, XP085984739
OPPOSITION- KANDA et al., "Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics", Journal of Biotechnology, (20070619), vol. 130, no. 3, doi:10.1016/j.jbiotec.2007.04.025, pages 300 - 10, XP022119693
OPPOSITION- Shields Robert L., Lai Jadine, Keck Rodney, O'connell Lori Y., Hong Kyu, Meng Y. Gloria, Weikert Stefanie H.A., Presta Leonard G., "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody-dependent Cellular Toxicity", J Biol Chem, (20020726), vol. 277, no. 30, pages 26733 - 26740, XP002689094
OPPOSITION- BECKER et al., "Fucose: biosynthesis and biological function in mammals", Glycobiology, (20030700), vol. 13, no. 7, doi:10.1093/glycob/cwg054, pages 41R - 53R, XP055114424
OPPOSITION- VON HORSTEN et al., "Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase", Glycobiology, (20101201), vol. 20, no. 12, doi:10.1093/glycob/cwq109, pages 1607 - 18, XP002612500
OPPOSITION- FRIEND et al., "Phase I Study of an engineered aglycosylated humanized CD 3 antibody in renal transplant rejection", Transplantation, (19991215), vol. 68, no. 11, doi:10.1097/00007890-199912150-00005, ISSN 0041-1337, pages 1632 - 7, XP009011271
OPPOSITION- IMAI-NISHIYA et al., "Double knockdown of alpha1,6 fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC", BMC Biotechnol., (20071130), vol. 7, no. 1, doi:10.1186/1472-6750-7-84, page 84, XP055787032
OPPOSITION- COSTA et al., "The impact of microcarrier culture optimization on the glycosylation profile of a monoclonal antibody", SpringerPlus, (20131200), vol. 2, no. 1, doi:10.1186/2193-1801-2-25, page 25, XP055345245
OPPOSITION- Da Silva Antonio, Kronthaler Ulrich, Koppenburg Vera, Fink Martin, Meyer Ines, Papandrikopoulou Anastassia, Hofmann Matthias, Stangler Thomas, Visser Jan, "Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013", Leukemia & Lymphoma, (20140700), vol. 55, no. 7, pages 1609 - 1617, XP055962264
OPPOSITION- Rosenlöcher Julia, Böhrsch Verena, Sacharjat Michael, Blanchard Véronique, Giese Christoph, Sandig Volker, Hackenberger Christian, Hinderlich Stephan, "Applying Acylated Fucose Analogues to Metabolic Glycoengineering", Bioengineering, (20150000), vol. 2, pages 213 - 234, XP055962265
OPPOSITION- Song Seong-Won, "Inhibition of Tumor Growth in a Mouse Xenograft Model by the Humanized Anti-HGF Monoclonal Antibody YYB-101 Produced in a Large-Scale CHO Cell Culture", J Microbiol Biotechnol, (20130000), vol. 23, no. 9, pages 1327 - 1338, XP055962250

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents